TY - JOUR
T1 - The Future of Nonalcoholic Fatty Liver Disease Treatment
AU - Mazhar, Khurram
N1 - Publisher Copyright:
© 2018
PY - 2019/1
Y1 - 2019/1
N2 - Nonalcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease in the United States. The NAFLD subtype, nonalcoholic steatohepatitis, represents a progressive form of the disease that can lead to cirrhosis, portal hypertension, and hepatocellular carcinoma. NAFLD is a diagnosis of exclusion and is strongly related to obesity and the metabolic syndrome. Although there has been an explosion of exciting therapeutic avenues for NAFLD in recent years, the bedrock of management continues to be lifestyle modification, weight loss, and optimization of metabolic risk factors.
AB - Nonalcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease in the United States. The NAFLD subtype, nonalcoholic steatohepatitis, represents a progressive form of the disease that can lead to cirrhosis, portal hypertension, and hepatocellular carcinoma. NAFLD is a diagnosis of exclusion and is strongly related to obesity and the metabolic syndrome. Although there has been an explosion of exciting therapeutic avenues for NAFLD in recent years, the bedrock of management continues to be lifestyle modification, weight loss, and optimization of metabolic risk factors.
KW - Fibrosis
KW - Metabolic syndrome
KW - Nonalcoholic fatty liver disease
KW - Nonalcoholic steatohepatitis
KW - Obesity
UR - http://www.scopus.com/inward/record.url?scp=85055736857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055736857&partnerID=8YFLogxK
U2 - 10.1016/j.mcna.2018.08.005
DO - 10.1016/j.mcna.2018.08.005
M3 - Review article
C2 - 30466676
AN - SCOPUS:85055736857
SN - 0025-7125
VL - 103
SP - 57
EP - 69
JO - Medical Clinics of North America
JF - Medical Clinics of North America
IS - 1
ER -